Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer

Shan Wang, Rahul K. Kollipara, Nishi Srivastava, Rui Li, Preethi Ravindranathan, Elizabeth Hernandez, Eva Freeman, Caroline G. Humphries, Payal Kapur, Yair Lotan, Ladan Fazli, Martin E. Gleave, Stephen R. Plymate, Ganesh Raj, Jer-Tsong Hsieh, Ralf Kittler

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The transcription factor E-twenty-six related gene (ERG), which is overexpressed through gene fusion with the androgen-responsive gene transmembrane protease, serine 2 (TMPRSS2) in ̃40% of prostate tumors, is a key driver of prostate carcinogenesis. Ablation of ERG would disrupt a key oncogenic transcriptional circuit and could be a promising therapeutic strategy for prostate cancer treatment. Here, we show that ubiquitin-specific peptidase 9, X-linked (USP9X), a deubiquitinase enzyme, binds ERG in VCaP prostate cancer cells expressing TMPRSS2-ERG and deubiquitinates ERG in vitro. USP9X knockdown resulted in increased levels of ubiquitinated ERG and was coupled with depletion of ERG. Treatment with the USP9X inhibitor WP1130 resulted in ERG degradation both in vivo and in vitro, impaired the expression of genes enriched in ERG and prostate cancer relevant gene signatures in microarray analyses, and inhibited growth of ERG-positive tumors in three mouse xenograft models. Thus, we identified USP9X as a potential therapeutic target in prostate cancer cells and established WP1130 as a lead compound for the development of ERGdepleting drugs.

Original languageEnglish (US)
Pages (from-to)4251-4256
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number11
DOIs
StatePublished - Mar 18 2014

Fingerprint

Prostatic Neoplasms
Transcription Factors
Genes
Ubiquitin
Peptide Hydrolases
Serine Proteases
Prostate
Deubiquitinating Enzymes
Neoplasm Genes
Gene Fusion
Microarray Analysis
Heterografts
Androgens
Neoplasms
Carcinogenesis
Gene Expression
Enzymes
Therapeutics
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. / Wang, Shan; Kollipara, Rahul K.; Srivastava, Nishi; Li, Rui; Ravindranathan, Preethi; Hernandez, Elizabeth; Freeman, Eva; Humphries, Caroline G.; Kapur, Payal; Lotan, Yair; Fazli, Ladan; Gleave, Martin E.; Plymate, Stephen R.; Raj, Ganesh; Hsieh, Jer-Tsong; Kittler, Ralf.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 11, 18.03.2014, p. 4251-4256.

Research output: Contribution to journalArticle

Wang, Shan ; Kollipara, Rahul K. ; Srivastava, Nishi ; Li, Rui ; Ravindranathan, Preethi ; Hernandez, Elizabeth ; Freeman, Eva ; Humphries, Caroline G. ; Kapur, Payal ; Lotan, Yair ; Fazli, Ladan ; Gleave, Martin E. ; Plymate, Stephen R. ; Raj, Ganesh ; Hsieh, Jer-Tsong ; Kittler, Ralf. / Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 11. pp. 4251-4256.
@article{8bc6c8ccf4fe467e8f06e60a2bb1273c,
title = "Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer",
abstract = "The transcription factor E-twenty-six related gene (ERG), which is overexpressed through gene fusion with the androgen-responsive gene transmembrane protease, serine 2 (TMPRSS2) in ̃40{\%} of prostate tumors, is a key driver of prostate carcinogenesis. Ablation of ERG would disrupt a key oncogenic transcriptional circuit and could be a promising therapeutic strategy for prostate cancer treatment. Here, we show that ubiquitin-specific peptidase 9, X-linked (USP9X), a deubiquitinase enzyme, binds ERG in VCaP prostate cancer cells expressing TMPRSS2-ERG and deubiquitinates ERG in vitro. USP9X knockdown resulted in increased levels of ubiquitinated ERG and was coupled with depletion of ERG. Treatment with the USP9X inhibitor WP1130 resulted in ERG degradation both in vivo and in vitro, impaired the expression of genes enriched in ERG and prostate cancer relevant gene signatures in microarray analyses, and inhibited growth of ERG-positive tumors in three mouse xenograft models. Thus, we identified USP9X as a potential therapeutic target in prostate cancer cells and established WP1130 as a lead compound for the development of ERGdepleting drugs.",
author = "Shan Wang and Kollipara, {Rahul K.} and Nishi Srivastava and Rui Li and Preethi Ravindranathan and Elizabeth Hernandez and Eva Freeman and Humphries, {Caroline G.} and Payal Kapur and Yair Lotan and Ladan Fazli and Gleave, {Martin E.} and Plymate, {Stephen R.} and Ganesh Raj and Jer-Tsong Hsieh and Ralf Kittler",
year = "2014",
month = "3",
day = "18",
doi = "10.1073/pnas.1322198111",
language = "English (US)",
volume = "111",
pages = "4251--4256",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "11",

}

TY - JOUR

T1 - Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer

AU - Wang, Shan

AU - Kollipara, Rahul K.

AU - Srivastava, Nishi

AU - Li, Rui

AU - Ravindranathan, Preethi

AU - Hernandez, Elizabeth

AU - Freeman, Eva

AU - Humphries, Caroline G.

AU - Kapur, Payal

AU - Lotan, Yair

AU - Fazli, Ladan

AU - Gleave, Martin E.

AU - Plymate, Stephen R.

AU - Raj, Ganesh

AU - Hsieh, Jer-Tsong

AU - Kittler, Ralf

PY - 2014/3/18

Y1 - 2014/3/18

N2 - The transcription factor E-twenty-six related gene (ERG), which is overexpressed through gene fusion with the androgen-responsive gene transmembrane protease, serine 2 (TMPRSS2) in ̃40% of prostate tumors, is a key driver of prostate carcinogenesis. Ablation of ERG would disrupt a key oncogenic transcriptional circuit and could be a promising therapeutic strategy for prostate cancer treatment. Here, we show that ubiquitin-specific peptidase 9, X-linked (USP9X), a deubiquitinase enzyme, binds ERG in VCaP prostate cancer cells expressing TMPRSS2-ERG and deubiquitinates ERG in vitro. USP9X knockdown resulted in increased levels of ubiquitinated ERG and was coupled with depletion of ERG. Treatment with the USP9X inhibitor WP1130 resulted in ERG degradation both in vivo and in vitro, impaired the expression of genes enriched in ERG and prostate cancer relevant gene signatures in microarray analyses, and inhibited growth of ERG-positive tumors in three mouse xenograft models. Thus, we identified USP9X as a potential therapeutic target in prostate cancer cells and established WP1130 as a lead compound for the development of ERGdepleting drugs.

AB - The transcription factor E-twenty-six related gene (ERG), which is overexpressed through gene fusion with the androgen-responsive gene transmembrane protease, serine 2 (TMPRSS2) in ̃40% of prostate tumors, is a key driver of prostate carcinogenesis. Ablation of ERG would disrupt a key oncogenic transcriptional circuit and could be a promising therapeutic strategy for prostate cancer treatment. Here, we show that ubiquitin-specific peptidase 9, X-linked (USP9X), a deubiquitinase enzyme, binds ERG in VCaP prostate cancer cells expressing TMPRSS2-ERG and deubiquitinates ERG in vitro. USP9X knockdown resulted in increased levels of ubiquitinated ERG and was coupled with depletion of ERG. Treatment with the USP9X inhibitor WP1130 resulted in ERG degradation both in vivo and in vitro, impaired the expression of genes enriched in ERG and prostate cancer relevant gene signatures in microarray analyses, and inhibited growth of ERG-positive tumors in three mouse xenograft models. Thus, we identified USP9X as a potential therapeutic target in prostate cancer cells and established WP1130 as a lead compound for the development of ERGdepleting drugs.

UR - http://www.scopus.com/inward/record.url?scp=84896502088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896502088&partnerID=8YFLogxK

U2 - 10.1073/pnas.1322198111

DO - 10.1073/pnas.1322198111

M3 - Article

VL - 111

SP - 4251

EP - 4256

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 11

ER -